Nuvo's second technology platform is based on a chlorite solution code-named WF10.

The immune system provides an essential defence to micro organisms, tumors and substances it sees as foreign and potentially harmful. Nuvo's immune regulation technology platform focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function.

WF10 is based on a chlorite solution of TCDO that appears to act on the macrophage, a white blood cell species with a central role in controlling the body's immune response. Normally functioning macrophages alternate between one of two basic states: phagocytic and inflammatory. Phagocytic macrophages digest invading organisms, such as viruses, and initiate a biological inflammatory defence pathway. Inflammatory macrophages, in turn, induce a variety of reactions, including fever, sweating, swollen glands, malaise and appetite loss, the common, uncomfortable signs of illness. Such responses, while entirely normal, must be turned on and off in a controlled manner. If left unchecked pathogens can overdrive the system toward the inflammatory state creating an imbalance that may lead to such medical disorders as autoimmune disease, organ damage and tumour proliferation. The Corporation's WF10 technology's proposed mode of activity is based on a theory about how the macrophage regulates the immune system. Research suggests the drug may correct improperly functioning immune systems. The drug has potential applications in adjuvant cancer therapy, immunology, and the management of chronic viral infections.